About Cartesian Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.cartesiantherapeutics.com/
Frequently Asked Questions
What is the 52-week range for RNAC?
The 52-week high is $11 and the 52-week low is $5.6.
What is the P/E ratio for RNAC?
The P/E ratio data is currently unavailable.
What is the dividend yield for RNAC?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -3215.82%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -8550.65%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.17.
Analyst Recommendation Trends
Wall Street analyst consensus for RNAC over the last few months:
Latest RNAC News
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees. On October 1, 2026, the Company issued to these employees options to purchase an aggregate of 121,900 shares of the Company’s common stock with an exercise price of $7.22, the closing trading price of the Company’s common s
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment Median interval between end of initial treatment course and first retreatment infusion was 16.6 months No new safety signals reported; safety profile consistent with previously reported data Topline data from Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis expected in 1Q27 FREDERICK,
Cartesian Therapeutics Presents Additional Retreatment Data Of Its Lead Investigational Asset, Descartes-08, In Patients With Generalized MG, During MGFA Scientific Session Of 2026 AANEM Annual Meeting
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatmentMedian interval between end
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-04-02 | Seven One Eight Three Four Irrevocable Trust | -22,740 | - | - |
| 2026-04-02 | Seven One Eight Three Four Irrevocable Trust | +758,001 | - | - |
| 2026-04-02 | Kalayoglu Murat | -22,740 | - | - |
| 2026-04-02 | Kalayoglu Murat | +758,001 | - | - |
| 2026-03-13 | Singer Michael | -6,555 | - | - |
| 2026-01-06 | Brunn Carsten | -23,766 | $6.8197 | $162,077 |
| 2026-01-06 | Miljkovic Milos | -3,573 | $6.8197 | $24,367 |
| 2026-01-06 | Davis Blaine | -10,591 | $6.8197 | $72,227 |
| 2026-01-02 | DeSilva Nishan M | +7,800 | - | - |
| 2026-01-02 | DeSilva Nishan M | +2,600 | - | - |
| 2026-01-02 | Brunn Carsten | +415,700 | - | - |
| 2026-01-02 | Brunn Carsten | +143,200 | - | - |
| 2026-01-02 | Malik Kemal | +7,800 | - | - |
| 2026-01-02 | Malik Kemal | +2,600 | - | - |
| 2026-01-02 | Miljkovic Milos | +77,000 | - | - |
| 2026-01-02 | Miljkovic Milos | +27,000 | - | - |
| 2026-01-02 | Seymour June Ann | +19,000 | - | - |
| 2026-01-02 | Seymour June Ann | +6,500 | - | - |
| 2026-01-02 | Davis Blaine | +109,000 | - | - |
| 2026-01-02 | Davis Blaine | +37,000 | - | - |
| 2026-01-02 | English Emily | +71,000 | - | - |
| 2026-01-02 | English Emily | +24,000 | - | - |
| 2026-01-02 | Singer Michael | +7,800 | - | - |
| 2026-01-02 | Singer Michael | +2,600 | - | - |
| 2026-01-02 | Kalayoglu Murat | +7,800 | - | - |
| 2026-01-02 | Kalayoglu Murat | +2,600 | - | - |
| 2026-01-02 | BARABE TIMOTHY C | +7,800 | - | - |
| 2026-01-02 | BARABE TIMOTHY C | +2,600 | - | - |
| 2026-01-02 | ZENNER PATRICK J | +7,800 | - | - |
| 2026-01-02 | ZENNER PATRICK J | +2,600 | - | - |
| 2026-01-02 | SPRINGER TIMOTHY A | +7,800 | - | - |
| 2026-01-02 | SPRINGER TIMOTHY A | +2,600 | - | - |
| 2025-12-30 | English Emily | -7,500 | - | - |
| 2025-12-30 | English Emily | +7,500 | $3.3 | $24,750 |
| 2025-12-16 | Bot Adrian Ion | +17,200 | - | - |
| 2025-12-16 | Bot Adrian Ion | +5,800 | - | - |
| 2025-12-04 | BARABE TIMOTHY C | +30,000 | $6.8599 | $205,797 |
| 2025-11-28 | English Emily | -7,500 | - | - |
| 2025-11-28 | English Emily | +7,500 | $3.3 | $24,750 |
| 2025-11-18 | Singer Michael | -20,000 | - | - |
| 2025-10-27 | Seymour June Ann | +50,000 | - | - |